Wednesday, October 30, 2013

eCrypt Technologies (ECRY) Provides a Data Security Fortress in an Increasingly Insecure Electronic Environment

At the forefront of data security, eCrypt Technologies is an emerging provider of military-strength data security solutions that address the needs of enterprise, government and military, helping these entities shore themselves up against potentially catastrophic information security breaches.

Enabling organizations to communicate and collaborate freely without risking liability, reputation damage, competitive threat or other undesirable outcomes, eCrypt has become a trusted “first choice” when it comes to keeping communications confidential. Using an ideas-based approach, eCrypt is constantly striving toward new solutions for evolving security problems. As organizations today struggle to guard themselves against the mounting dangers, eCrypt’s solutions can be invaluable in addressing the data breaches that cost U.S. businesses, on average, more than $500 million each year.

The company’s flagship eCrypt One solution is a military-strength e-mail and encryption system that can be deployed quickly to safeguard an organization’s corporate communication – including attachments and mobile devices – against data breaches while also eliminating phishing threats, malware infections and spam. eCrypt One eradicates the need for multiple encryption servers, which frequently come with their own associated bloated administrations and points of weakness.

In addition to its solutions, eCrypt provides security consulting services to help organizations overcome security and compliance challenges and safeguard their administration-critical information. It is estimated that nearly half of an organization’s worth is derived from the information it stores, making data breaches potentially ruinous.

eCrypt is well-positioned to capitalize in this age of increasingly stringent data confidentiality regulations, such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and the Gramm-Leach-Bliley Act (GLBA). Leveraging extensive market research, as well as its relationships with key industry experts and leaders, eCrypt fully understands the business community’s needs for maintaining confidentiality, preventing data breaches, complying with government regulations, and mitigating litigation risks. The company works directly with organizations in multibillion-dollar industries to safeguard them against the information security breaches that can spell disaster.

For more information about eCrypt, visit www.ecryptinc.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

OxySure Systems, Inc. (OXYS) Avoids Complexities of Traditional Systems for Dental or Medical Office Emergencies

A recent article promoting the importance of emergency oxygen for dental offices broke down some of the things involved in adequately providing for such situations using traditional oxygen tanks, information applicable to similar environments.

First of all it emphasized the need of having a separate portable oxygen system that is dedicated to dealing with emergencies, indicating that a standard centralized system that depends on H-size oxygen cylinders might not have the necessary reach for a patient in a waiting room or other area. Moreover, such centralized systems might not offer the positive pressure required for proper resuscitation, and that a portable cylinder, including a bag-valve-mask resuscitator or demand valve, is better. It also spoke about mobile oxygen carts to provide mobility for larger oxygen tanks. Not mentioned, but equally important, are the steps required to safely maintain traditional pressurized oxygen equipment and ensure that staff is properly trained in its use and upkeep.

OxySure has what it is convinced is a better answer, not only for medical offices but for virtually any public or private location that might face an oxygen emergency, such as someone having an asthma or heart attack. The OxySure approach avoids pressurized tanks, and all of the safety and maintenance issues involved with them. The company instead uses a patented technology that delivers medically pure oxygen instantly, on demand, from two dry and inert powders. Their system is so simple that any layperson is able to use it quickly and safely. There’s no risk of tanks ever overheating and exploding, and there’s virtually no maintenance, and no hydrostatic testing, batteries, or other complexities. It’s always ready to use, easy to move, and a breeze to operate. And the system’s small size and lightweight also makes it easy to store, meaning that multiple units can be kept on site to fit any extended use or other emergency scenarios.

For more information, visit www.oxysure.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Singlepoint, Inc. (SING) Video Chart for Wednesday, October 30, 2013

SING has retraced from highs at 2.2 cents in May back to a strong support level around $0.004. The indicators are hinting towards a shift to bullishness off the base again as the chart looks to be forming a double bottom as the 50-day moving average enters the mix, putting technical traders on alert for potential pps movement.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Tuesday, October 29, 2013

Boston Therapeutics, Inc. (BTHE) Pioneering Treatment of Diabetes, Directed by Experienced Leader

According to the American Diabetes Association, 25.8 million children and adults in the United States have diabetes. Around 27% of that population remains undiagnosed (7 million people), and 79 million people are estimated to be classified as pre-diabetic. In 2007 alone, diabetes was either listed as an underlying cause or contributing factor to over 231,000 deaths, a stark indicator of the life-threatening risk of this condition.

Other figures show the economic impact of diabetes. According to figures supplemented in March 2013, the total costs of diabetes in the United States in 2012 was $245 billion, of which $176 billion was classified as direct medical costs and $69 billion classified as costs arising from diabetics’ reduced quality of life. After they made adjustments for population and sex differences, researchers found that people with diagnosed diabetes spent 2.3 times more on medical expenditures than those without diabetes.

In other words, it’s clear that diabetes is a well-entrenched health risk in just America alone. With leading diabetes complications such as heart disease and high blood pressure on the rise, the need for effective therapeutic treatment as well preventive measures is becoming increasingly more mainstream and compelling.

Boston Therapeutics, billing itself as “a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes,” is working to develop a solution that exhibits potential in being a pioneering solution to the ever-growing diabetes outbreak. That solution is namely the company’s PAZ320, a non-systemic, non-toxic, chewable drug for prevention of diabetes and its complications. This polysaccharide targets enzymes that digest sugar during digestion, thereby reducing the amount of available glucose for the intestine to absorb. This capability positions the PAZ320 as a prospective solution for slowing the onset of Type 2 diabetes and/or the development of diabetes complications (e.g., heart disease, stroke, kidney damage, retinopathy, and Diabetic Foot).

In addition to exhibiting strong potential in its R & D efforts, Boston Therapeutics is also led by a highly experienced and successful management and scientific advisory team with lengthy expertise in complex carbohydrate chemistry, regulatory, and clinical development. The team’s members have had numerous marked successes in submitting and obtaining approval for multiple drug candidates to the U.S. Food and Drug Administration. Collectively Boston Therapeutics’ executive management team has more than 100 years of combined experience of c-level executive leadership, corporate finance and company operations finessing, bio-medical product innovation, and corporate consulting, among other field focuses.

To illustrate Boston Therapeutics’ leadership expertise, consider Dr. David Platt, chairman, CEO, CFO and company director. He is a world-renowned expert in carbohydrate chemistry and has founded three publicly held companies, generating almost $1 billion for shareholders in those enterprises. He has also led two drug candidates from concept to human clinical trials.

With a strongly experienced management and medical science advisory board behind its efforts, and the strong potential that its PAZ320 might hold for treating diabetes, Boston Therapeutics is positioned at the threshold of delivering one of the most far-reaching innovations in bio-medical solutions in decades, and enjoying the strong profitability that would come with such an accomplishment.

For more information visit www.bostonti.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Intelimax Media, Inc. (IXMD) Sees Unlimited Market in Fantasy Sports

In the U.S., it’s easy to think of sports strictly from an American viewpoint, forgetting that there’s an entire world out there just as passionate about soccer and other world sports as the average American is about football, basketball, or baseball. Spectator sports in the U.S. represent an industry totaling tens of billions of dollars annually, and still growing. But globally it’s well over $100 billion.

The scale of such figures has fueled one of the fastest growing auxiliary industries, fantasy sports, already a multi-billion dollar industry in its own rite. In fantasy sports, people build their own fantasy sports teams using continually changing player statistics to compete with other fantasy teams. Originally confined to sports and number fanatics in the U.S., the once niche pastime has now been driven to global proportions, thanks to computer processing and advanced communication technology. Although still predominantly American, fantasy sports competition has established a major presence in Canada and the UK, and is now gaining attention in countries around the world. The technologies can be applied to virtually any competitive sport, and the Internet reaches all corners of the globe.

This is all good news for Intelimax Media, Canadian-based developers of DraftTeam.com, a proprietary fantasy sports platform. The company’s unique system allows players to compete on a daily or weekly basis, versus limiting them to full season participation. It makes it more attractive to new players who may want to give fantasy sports a meaningful try without locking themselves in. In addition, the platform is designed to generate multiple revenue streams.

At this point Intelimax sees no limit to their potential market, and the company’s plans for international expansion are already underway.

For more information, visit www.Intelimax.com.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Marathon Patent Group, Inc. (MARA) is “One to Watch”

Marathon Patent Group services a broad array of patent owners to help them license their portfolios, from individual inventors up to Fortune 500 companies. Marathon, via its operating subsidiaries, also acquires or invests in promising patent assets/rights with the ultimate objective of generating licensing revenues.

Since its inception, the company has been quite busy sourcing top-shelf patent portfolios via channels. An example would be their tight-knit working relationship with one of the global leaders in full-service patent monetization, IPNav, and its CEO, Erich Spangenberg, who is part of that relationship stretching back to 1998.

The experienced licensing team at MARA has devised an extremely rigorous vetting process involving collaborative due diligence, which also relies heavily on the established licensing strategies developed by IPNav – strategies that have helped IPNav pull down some $620M in settlements over the last decade alone.

MARA’s current patent load out, amassed either via direct upfront payment or through participation in revenue generation for the patent sellers, currently tips the scales at some 35 U.S. patents and 64 international patents. Just last week (Oct 22) MARA reaffirmed its patent licensing prowess to markets yet again with the acquisition of a portfolio of four U.S. patents in the process automation (production) and enterprise resource planning area, dealing with the implementation of adaptive learning methods. This marks the third portfolio the company (or one of its operating subsidiaries) has snapped up in just the four weeks preceding the announcement itself.

Marathon is a lean, mean and appropriately aggressive outfit that has a solid balance sheet and no debt. With Q2 figures on display, MARA is reporting the first real quarter during which the company has reported significant licensing and settlement revenues. This profile provides investors with a clear glimpse of MARA’s financial status via 33 active lawsuits and over 42 different defendants (reported Aug 15). With gross revenue that broke $1.5M on settlement and licensing proceeds, it should be obvious where this company is headed. In fact, MARA pushing numbers like that in their first real quarter of patent enforcement activity should be a major signal to investors that both the strength of their patents and the veracity of their enforcement capabilities are something to keep a close eye on in coming months. The sheer speed with which Marathon has managed to drop the hammer on monetization of their portfolio says it all.

Earlier in August (Aug 2) the company’s newly launched campaign for wholly-owned subsidiary Relay IP Inc., resulted in filing of a patent infringement lawsuit against leading New York metropolitan area telecommunications and media company, Cablevision, over their Internet protocol network multicasting territory (USPTO #5,331,637 – multicast routing using core-based trees). This was just shortly after the company’s initial Relay IP victory in July, a short three months into the launch of the new licensing campaign, as Relay IP successfully entered into a settlement and license agreement with a top tech firm over the Relay IP patent. Another patent infringement lawsuit in Relay IP, this time against 10 major named defendants and filed in June (including big names like The Nasdaq OMX Group, Inc. and BATS Trading Inc.) offers yet more tangible evidence of the strength of MARA’s position. Relay IP territory is essentially IP multicast and this patent position has huge coverage in the growing world of IPTV applications like distance learning or televised company meetings. It is also the most widely used protocol in Protocol Independent Multicast or PIM.

Earlier in the year (May 30), MARA acquired three U.S. and ten international patents from undisputed global electronics and electrical engineering heavyweight, Siemens, via their wholly-owned Bismarck IP subsidiary. The three patents relate to enhancement features and performance technologies in switching communication terminal equipment and Private Branch Exchanges (PBXs). Trusted ally IPNav has already been tapped to help MARA monetize this fertile patent territory and the strategic might of the company’s overall patent position should be self-evident when also taking into account their Sampo IP and Cyberfone assets (covering areas of distributed application communications and menu/form-driven data transactions respectively). IPNav’s sophisticated toolset includes their custom IPNav Analyzer, a patent analytics and market analysis engine, as well as their transaction and licensing agreement database which spans multiple industries and technology areas.

Founder and CEO of MARA, Doug Croxall, marveling at the robust and highly scalable IP monetization platform the company has put together, emphasized the 6.4M in cash the company had on hand as of late June. Add to that the lack of debt on their balance sheet, and these leading indicators reveal how spry MARA will be in terms of portfolio expansion and monetization this year and on into 2014.

A diverse yet strategically relevant portfolio that is constantly growing, and a close partnership with patent monetization juggernaut IPNav spell out tremendous upside in a world increasingly dependent on distributed information and communication technologies. Marathon’s modular approach to territory acquisition via outright purchase or partnering with the patent holder, ultimately resulting in actively managed patent licensing campaigns, is a brilliant model, and this Alexandria, Virginia-based company has the executive muscle to support their inevitable growth dynamics as well. Croxall himself cut his teeth in the industry with powerhouses like KPMG and Motorola, then moved on to head up Firepond, where he achieved some $90M in patent licensing revenues from 2004 to 2009 before going on to found his own successful,  privately-owned patent holding company, LVL Patent Group.

The company’s Sampo IP assets (Sampo IP, LLC) saw the first and second settlement agreements landed within four months of the kick off of their licensing campaign in March, and these assets in particular represent a rapidly evolving area for MARA where ongoing infringement continues on the centrifugal communication and collaboration method patents. These patents cover facilitation of communication between members of a distributed discussion group using communication devices and a central agent.

The Cyberfone assets (CyberFone Systems, LLC) cover a range of certain transactional data processing, telecommunications, network and database inventions, and includes financial transactions and enforcement which is open-ended against such high-profile named defendants as Alcatel-Lucent, Mitsubishi, Toshiba, and UPS. The settlement achieved with Denon Electronics, LLC in June of this year on the Cyberfone assets illustrated how secure the company’s patent position is and the truly foundational digital communications and data transaction processing areas covered by this portfolio for the finance, telecom, and wireless sectors alone are enormous.

Learn more about Marathon Patent Group, Inc. at www.MarathonPG.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Dot Hill (HILL) AssuredSAN Pro 5000 Selected by C7 Data Centers for Private Cloud Solution

Dot Hill Systems Corp. (HILL), a prominent supplier of SAN storage products, announced today that its AssuredSAN Pro 5000 Series 100 terabyte offering has been selected by C7 Data Centers, a leader in outsourced IT solutions, for incorporation into C7’s new private cloud configuration. Dot Hill’s AssuredSAN Pro 5000 Series features real-time automated tiering for single tenant private cloud solutions, making it an ideal selection for C7’s new offering which provides affordable cloud-based redundancy in both physical and virtual production environments.

“Many companies are looking at cloud implementations to grow IT resources without increasing support and hardware costs,” said Jim Jonez, senior director of marketing, Dot Hill. “C7 Data Centers and Dot Hill are working together to provide a responsive, reliable, and cost-effective infrastructure. The Dot Hill AssuredSAN Pro 5000 Series allows cloud customers to increase capacity without having to purchase additional licenses, providing savings to their bottom line.”

“We’re confident that in our FuseApp Private Cloud and Private Cloud Suite solutions we’ve found the right mix of technologies to provide a robust, affordable failover solution for physical and virtual production environments that is easy to scale,” said Wes Swenson, CEO, C7 Data Centers. “The Dot Hill AssuredSAN Pro 5000 Series provides 99.999 percent availability and real-time tiering — features that meet the performance requirements of a production site.”

The AssuredSAN Pro 5000 Series has built-in intelligence that automatically adjusts to data access needs without human involvement or policy modification. The AssuredSAN Pro Series, with RealStor™ software raises the bar on tiered storage, above other automated off-hours batch migration tiered storage systems, and up to a new level of autonomic, real-time data tiering.

The AssuredSAN Pro 5000 Series is a cutting edge, high-performance integrated storage array that consistently delivers faster access to up-to-date data with built-in, real-time autonomic tiered storage and virtualization. This highly available and reliable solution immediately detects priorities for data access to optimize the delivery of high demand data in real time. Faster I/O is achieved in part through real-time automated data tiering, which prioritizes data files, volumes or blocks between tiered storage using built-in analysis and data scoring.

For further information, please visit www.dothill.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net